BriaCell Therapeutics Corp.

NasdaqCM:BCTX Stock Report

Market Cap: US$31.3m

BriaCell Therapeutics Management

Management criteria checks 4/4

BriaCell Therapeutics' CEO is Bill Williams, appointed in Oct 2016, has a tenure of 9.92 years. total yearly compensation is $780.62K, comprised of 91.2% salary and 8.8% bonuses, including company stock and options. directly owns 0.4% of the company’s shares, worth $126.75K. The average tenure of the management team and the board of directors is 9.9 years and 7.5 years respectively.

Key information

Bill Williams

Chief executive officer

US$780.6k

Total compensation

CEO salary percentage91.17%
CEO tenure9.9yrs
CEO ownership0.4%
Management average tenure9.9yrs
Board average tenure7.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Bill Williams's remuneration changed compared to BriaCell Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Apr 30 2026n/an/a

-US$31m

Jan 31 2026n/an/a

-US$30m

Oct 31 2025n/an/a

-US$29m

Jul 31 2025US$781kUS$712k

-US$26m

Apr 30 2025n/an/a

-US$19m

Jan 31 2025n/an/a

-US$12m

Oct 31 2024n/an/a

-US$17m

Jul 31 2024US$1mUS$734k

-US$5m

Apr 30 2024n/an/a

-US$6m

Jan 31 2024n/an/a

-US$13m

Oct 31 2023n/an/a

-US$13m

Jul 31 2023US$1mUS$737k

-US$20m

Apr 30 2023n/an/a

-US$18m

Jan 31 2023n/an/a

-US$23m

Oct 31 2022n/an/a

-US$412k

Jul 31 2022US$811kUS$561k

-US$27m

Apr 30 2022n/an/a

-US$42m

Jan 31 2022n/an/a

-US$30m

Oct 31 2021n/an/a

-US$41m

Jul 31 2021US$830kUS$218k

-US$14m

Apr 30 2021n/an/a

US$2m

Jan 31 2021n/an/a

-US$2m

Oct 31 2020n/an/a

-US$3m

Jul 31 2020US$231kUS$231k

-US$4m

Compensation vs Market: Bill's total compensation ($USD780.62K) is about average for companies of similar size in the US market ($USD650.37K).

Compensation vs Earnings: Bill's compensation has been consistent with company performance over the past year.

CEO

Bill Williams (71 yo)

9.9yrs
Tenure
US$780,622
Compensation

Dr. William V. Williams, M.D., FRCP, FACP also known as Bill, has been the Chief Executive Officer and President of BriaCell Therapeutics Corp. since October 2016 and serves as its Director Since November...

Leadership Team

NamePositionTenureCompensationOwnership
William Williams
CEO, President & Director9.9yrsUS$780.62k0.40%
$ 126.7k
Gadi Levin
CFO & Corporate Secretary10.6yrsUS$535.36k0.11%
$ 34.0k
Miguel Lopez-Lago
Chief Scientific Officer4.3yrsUS$447.55k0.11%
$ 33.9k
Giuseppe Del Priore
Chief Medical Officer4.6yrsUS$493.05k0.22%
$ 67.8k
Charles Wiseman
Founder11.3yrsUS$241.14kno data
9.9yrs
Average Tenure
64yo
Average Age

Experienced Management: BCTX's management team is seasoned and experienced (9.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Williams
CEO, President & Director9.8yrsUS$780.62k0.40%
$ 126.7k
Charles Wiseman
Founder5.7yrsUS$241.14kno data
Brian Metcalf
Member of Scientific Advisory Board9.3yrsno datano data
Martin Schmieg
Independent Director5.8yrsUS$143.90k0.000030%
$ 9.4
Rebecca Taub
Independent Director7.5yrsUS$118.90k0%
$ 0
Vaughn Embro-Pantalony
Lead Independent Director7.5yrsUS$154.21k0.0019%
$ 585.5
Douglas Faller
Member of Scientific Advisory Board9.3yrsno datano data
Jane Gross
Independent Director4.7yrsUS$123.89k0.00076%
$ 238.0
Thomas Kieber-Emmons
Member of Scientific Advisory Board9.3yrsno datano data
Maria Trojanowska
Member of Scientific Advisory Board9.3yrsno datano data
Jamieson Bondarenko
Independent Chairman of the Board7.6yrsUS$948.37k0.013%
$ 4.1k
Cara Haymaker
Member of Scientific Advisory Board7yrsno datano data
7.5yrs
Average Tenure
71yo
Average Age

Experienced Board: BCTX's board of directors are considered experienced (7.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/11 16:04
End of Day Share Price 2026/09/11 00:00
Earnings2026/04/30
Annual Earnings2025/07/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BriaCell Therapeutics Corp. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Emily BodnarH.C. Wainwright & Co.
Ashok KumarThinkEquity LLC